A new study finds disruptions in health insurance coverage are common in the United States and are associated with poorer cancer care and survival. The study was published in The Journal of the National Cancer institute.
A study from UT Southwestern researchers shows that artificial intelligence can identify a specific genetic mutation in a glioma tumor simply by examining 3D images of the brain—with more than 97% accuracy.
Researchers have demonstrated a novel approach in mouse models that delivers appropriately-targeted chimeric antigen receptor CAR T-cell therapy directly into the cerebrospinal fluid that surrounds the tumor in an effort to treat medulloblastoma and ependymoma.
CheckMate -743, a phase III trial evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in previously untreated malignant pleural mesothelioma met its primary endpoint of overall survival.
The phase III CheckMate-9ER trial evaluating Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma met its primary endpoint of progression-free survival at final analysis.
In its first clinical trial in patients with a hard-to-treat form of uterine cancer, a targeted drug that subjects tumor cells to staggering levels of DNA damage caused tumors to shrink in nearly one-third of patients, investigators at Dana-Farber Cancer Institute report.
A team of investigators from Winship Cancer Institute of Emory University has shown outstanding long term survival results for multiple myeloma patients from a 3-drug induction regimen in a study published in the Journal of Clinical Oncology.
Cue Biopharma Inc. and Merck are evaluating the combination of Cue Biopharma's investigational product candidate CUE-101, a first-in-class biologic, with Merck's Keytruda in patients with advanced head and neck cancer.
Elicio Therapeutics and NCI are working together to characterize T cell responses to ELI-002 in animals.
Juul sales recovered within weeks following a dip after the company withdrew some flavored products from stores, eventually surpassing sales from before the change, according to a study by American Cancer Society researchers in the American Journal of Public Health.